Astria Therapeutics Inc., a biopharmaceutical company specializing in therapies for allergic and immunologic diseases, has granted stock options as part of its 2022 Inducement Stock Incentive Plan. On May 1, 2025, the company awarded options to purchase 33,650 shares of its common stock to three new employees as an inducement for joining Astria. These options, with an exercise price set at $5.16 based on the closing stock price on the grant date, will vest over four years. Initial vesting of 25% occurs on the first anniversary of the employees' start date, with the remainder vesting monthly over the subsequent 36 months, contingent upon continued employment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.